SV Life Sciences was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. The company's first fund closed in 1994 raising $100m. SV Life Sciences now has five funds with current committed capital of approximately $1.5 billion. Its team of 32 professionals are located in offices in Boston, London and San Francisco. SV Life Sciences became independent of the Schroder Ventures Group in 2001, and in January 2005 changed its name to SV Life Sciences to reflect independent ownership.
SV Life Sciences is a venture capital adviser and manager that makes selected investments in entrepreneurs and management teams.
SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services.
SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.5 billion which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions.
Our team of 32 professionals has a diverse, complimentary set of skills and experience that allow us to tailor a team to work with almost any life sciences business.
Brexit can significantly increase tuna prices United Kingdom
The countdown of the UK departure from the EU will actually begin - the deadline is 11 noon (London time) on October 31, 2019 - and the country is worried that it will face the Brexit without any agre...